Abstract
Benjamin Pulli, Gabriel Courties, Benoit Tricot, Matthew Sebas, Yoshiko Iwamoto, Ingo Hilgendorf, Stefan Schob, Athanasia Skoura, Amit Kalgukar, Christian Cortes, Roger Ruggeri, Filip K. Swirski, Matthias Nahrendorf, Leonard Buckbinder, John W. Chen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy
10.1161/01.cir.101.25.2981 · 2000
Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities
10.1007/s10741-010-9181-7 · 2011
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
10.1056/nejmoa043938 · 2005
Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study
10.1093/aje/kwt109 · 2013
Long-term trends in the incidence of heart failure after myocardial infarction
10.1161/circulationaha.108.784215 · 2008
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials
10.1016/s0140-6736(03)12113-7 · 2003
National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998–2010
10.1161/circulationaha.113.003668 · 2013
Potential novel pharmacological therapies for myocardial remodelling
10.1093/cvr/cvn317 · 2009
Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure
10.1126/science.1230719 · 2013
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury
10.1161/circulationaha.107.756510 · 2008
Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice
10.1172/jci42304 · 2010
Myeloperoxidase and cardiovascular disease
10.1161/01.atv.0000163262.83456.6d · 2005
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction
10.1084/jem.20021426 · 2003
Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase
10.1074/jbc.m106958200 · 2001
Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction
10.1161/circulationaha.105.542340 · 2005
Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?
10.1373/clinchem.2009.126029 · 2009
Association between myeloperoxidase levels and risk of coronary artery disease
10.1001/jama.286.17.2136 · 2001
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes
10.1161/01.cir.0000090690.67322.51 · 2003
Prognostic value of myeloperoxidase in patients with chest pain
10.1056/nejmoa035003 · 2003
PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis
10.1124/jpet.114.221788 · 2015
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acet amide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases
10.1021/acs.jmedchem.5b00963 · 2015
Measuring myeloperoxidase activity in biological samples
10.1371/journal.pone.0067976 · 2013
Myeloperoxidase: the good, the bad, and the ugly
10.2174/157339510791111691 · 2010
Myeloperoxidase: friend and foe
10.1189/jlb.1204697 · 2005
Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity
10.1182/blood-2010-06-290171 · 2011
Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target
10.1148/radiol.12111593 · 2012
Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase
10.1073/pnas.0803945105 · 2008
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
10.1084/jem.20070885 · 2007
Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis
10.1016/j.jacc.2009.08.089 · 2010
Ly-6Chigh monocytes depend on nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium
10.1161/circresaha.114.303204 · 2014
MARCOing monocytes for elimination
10.1126/scitranslmed.3008448 · 2014
Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype
10.1093/eurheartj/ehw002 · 2016
Myeloperoxidase attracts neutrophils by physical forces
10.1182/blood-2010-05-284513 · 2011
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans
10.1161/01.cir.0000140262.20831.8f · 2004
Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro
10.1172/jci5549 · 1999
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease
10.1172/jci200421109 · 2004
The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport
10.1073/pnas.0405292101 · 2004
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure
10.1016/j.jacc.2007.02.053 · 2007
Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function
10.1016/j.freeradbiomed.2007.07.016 · 2007
Myeloperoxidase: a target for new drug development?
10.1038/sj.bjp.0707358 · 2007
No additional external references are available.